LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

Inicio・Lista de Acciones・Roivant Sciences Ltd

Roivant Sciences Ltd

Cerrado

SectorSanidad

27.83 -2.66

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

27.83

Máximo

28.12

Métricas clave
By Trading Economics
Ingresos	-200M -314M
Ventas	428K 2M
Margen de beneficios	-15,692.896
Empleados	750
EBITDA	-132M -290M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+22.36% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	5B 20B
Apertura anterior	30.49
Cierre anterior	27.83

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

310 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

11 / 11.18 Soporte y Resistencia

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2026, 23:43 UTC

Noticias de Eventos Importantes

New Zealand's Unemployment Rate Falls in 1Q

5 may 2026, 23:20 UTC

Acciones populares

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 may 2026, 21:48 UTC

Ganancias

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 may 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 may 2026, 00:00 UTC

Charlas de Mercado

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 may 2026, 23:39 UTC

Charlas de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 may 2026, 22:26 UTC

Charlas de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 may 2026, 22:20 UTC

Charlas de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 may 2026, 22:08 UTC

Ganancias

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 may 2026, 22:07 UTC

Ganancias

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Rev $1.2B >PAAS

5 may 2026, 21:42 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:38 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:30 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:29 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:26 UTC

Ganancias

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q EPS 39c >ALC.EB

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 may 2026, 21:24 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:18 UTC

Ganancias

Mistras Backs 2026 Rev $730M-$750M >MG

5 may 2026, 21:17 UTC

Ganancias

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 may 2026, 21:15 UTC

Ganancias

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 may 2026, 21:12 UTC

Ganancias

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 may 2026, 21:11 UTC

Ganancias

SSR Mining 1Q Rev $581.8M >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q EPS $1.16 >SSRM

5 may 2026, 21:08 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:01 UTC

Ganancias

Intact Financial 1Q EPS C$4.12 >IFC.T

5 may 2026, 21:01 UTC

Acciones populares

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

22.36% repunte

Estimación a 12 Meses

Media 34.7 USD 22.36%

Máximo 41 USD

Mínimo 29 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Roivant Sciences Ltd Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

310 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.